Maternal thrombophilia and neonatal thrombosis

Best Practice and Research: Clinical Haematology

Volumn 16, Issue 2, 2003, Pages 333-345

  Heller, Christine ^a   Nowak Göttl, Ulrike ^b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Neonatal thrombosis; Prothrombotic risk factors; Therapy; Underlying diseases

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; ANTITHROMBIN; ASPARAGINASE; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR CONCENTRATE; ENOXAPARIN; FIBRINOLYTIC AGENT; HEPARIN; LIPOPROTEIN A; LOW MOLECULAR WEIGHT HEPARIN; PREDNISONE; PROTEIN C; PROTEIN S; PROTHROMBIN; STREPTOKINASE; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; WARFARIN;

AGE DISTRIBUTION; ANTITHROMBIN DEFICIENCY; BLEEDING; CLINICAL PROTOCOL; FEMALE; FETUS WASTAGE; GENE MUTATION; HUMAN; INDIVIDUALIZATION; INFANT DISEASE; INTRAUTERINE GROWTH RETARDATION; LABORATORY TEST; LONG TERM CARE; MATERNAL DISEASE; NEWBORN DISEASE; PRACTICE GUIDELINE; PREMATURITY; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REFERENCE VALUE; REVIEW; RISK FACTOR; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOGENESIS; THROMBOPHILIA; THROMBOSIS; ARTERY THROMBOSIS; HEMOSTASIS; INHERITANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PHLEBOGRAPHY; PREGNANCY COMPLICATION; SCREENING;

EID: 0038656422     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6926(02)00096-8     Document Type: Review

References (72)

1. Schmidt B & Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry. Pediatrics 1995; 95: 936-943.
2. Nowak-Göttl U, von Kries R & Göbel U. Neonatal symptomatic thromboembolism in Germany: two year survey. Archives of Disease in Childhood 1997; 76: F163-F167.
3. van Ommen H, Heijboer H, Büller HR et al. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. Journal of Pediatrics 2001; 139: 676-681.
4. Andrew M. Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Thrombosis and Haemostasis 1995; 74: 415-425.
5. Salafia CM, Vintzileos AM, Silberman L et al. Placental pathology of idiopathic intrauterine growth retardation at term. American Journal of Perinatology 1992; 9: 179-184.
6. Brenner B, Sarig G, Wiener Z et al. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause. Thrombosis and Haemostasis 1999; 82: 6-9.
7. Dizon-Townson DS, Meline L, Nelson LM et al. Foetal carriers of the factor V Leiden are prone to miscarriage and placental infarction. American Journal of Obstetrics and Gynecology 1997; 177: 402-405.
8. Berg K, Roland B & Sande H. High Lp(a) lipoprotein level in maternal serum may interfere with placental circulation and cause fetal growth retardation. Clinical Genetics 1994; 46: 52-56.
9. Pabinger I, Grafenhofer H, Kaider A et al. Preeclampsia and fetal loss in women with a history of venous thromboembolism. Arteriosclerosis, Thrombosis and Vascular Biology 2001; 21: 874-879.
10. Göpel W, Kim D & Gortner L. Prothrombotic mutations as a risk factor for preterm birth. Lancet 1999; 353: 1411-1412.
11. Verspyck E, Le Camp-Duchez V, Gravier A et al. Small for gestational age infant in association with maternal prothrombin gene variant (nt 20210A). European Journal of Obstetrics and Gynecology and Reproductive Biology 1999; 83: 143-144.
12. Kries von R, Junker R, Oberle D et al. Foetal growth restriction in children with prothrombotic risk factors. Thrombosis and Haemostasis 2001; 86: 1012-1016.
13. Vries de LS, Eken P & Groenendaal F. Antenatal onset of haemorrhagic and/or ischaemic lesions in preterm infants: prevalence and associated obstetric variables. Archives of Disease in Childhood 1998; 78: F51-F56.
14. Kraus FT & Acheen VI. Fetal thrombotic vasculopathy in the placenta: cerebral thrombi and infarcts, coagulopathies, and cerebral palsy. Human Pathology 1999; 30: 759-769.
15. Debus O, Koch HG, Kurlemann G etal. Factor V Leiden and genetic defects ofthrombophilia in childhood porencephaly. Archives of Disease in Childhood 1998; 78: F121-F124.
16. Govaets P, Matthys E, Zecic A et al. Perinatal cortical infarction within middle cerebral artery trunks. Archives Disease in Childhood 2000; 82: F59-F63.
17. Brenner B, Hoffman R, Blumenfeld Z et al. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thrombosis and Haemostasis 2000; 83: 693-697.
18. Pauzner R, Dulitzki M, Langevitz R et al. Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy. Thrombosis and Haemostasis 2001; 86: 1379-1384.
19. Ries M, Klinge J & Rauch R. Age-related reference values for activation markers of the coagulation and fibrinolytic systems in children. Thrombosis Research 1997; 85: 341-344.
20. Schwarz HP, Muntean W, Watzke H et al. Low total protein S antigen but higher protein S activity due to decreased c4b-binding protein in neonates. Blood 1988; 71: 562-565.
21. Cvirn G, Gallistl S & Muntean W. Effects of antithrombin and protein C on thrombin generation in newborn and adult plasma. Thrombosis Research 1999; 93: 183-190.
22. Andrew M, Schmidt B, Mitchell L et al. Thrombin generation in newborn plasma is critically dependent on the concentration of prothrombin. Thrombosis and Haemostasis 1990; 63: 27-30.
23. Ries M, Klinge J, Rauch R et al. In vitro fibrinolysis after adding low doses of plasminogen activators and plasmin generation with and without oxidative inactivation of plasmin inhibitors in newborns and adults. Journal of Pediatric Hematology Oncology 1996; 18: 346-351.
24. Nowak-Göttl U, Dübbers A, Kececioglu D et al. Factor V Leiden, protein C and lipoprotein (a) in catheter related thrombosis in childhood-a prospective study. Journal of Pediatrics 1997; 131: 608-612.
25. Vitiello R, McCrindle BW, Nykanen D et al. Complications associated with pediatric cardiac catheterization. Journal of the American College of Cardiology 1998; 32: 1433-1440.
26. Salonvaara M, Riikonen P, Kekomaki R et al. Clinical symptomatic central venous catheter-related deep venous thrombosis in newborns. Acta Paediatrica 1999; 88: 642-646.
27. Boo NY, Wong NC, Zulkifli SS et al. Risk factors associated with umbilical vascular catheter-associated thrombosis in newborn infants Journal of Paediatrics and Child Health 1999; 35: 460-465.
28. Schwartz DS, Gettner PA, Konstantino MM et al. Umbilical venous catheterization and the risk of portal vein thrombosis. Journal of Pediatrics 1997; 131: 760-762.
29. Schlegel N. Thromboembolic risks and complications in nephrotic children. Seminars in Thrombosis and Haemostasis 1997; 23: 271-280.
30. Sträter R, Vielhaber H, Kassenböhmer R et al. Genetic risk factors of thrombophilia in ischaemic childhood stroke of cardiac origin. A prospective ESPED survey. European Journal of Pediatrics 1999; 158: S122-S125.
31. Manco-Johnson M, Abshire T, Jacobson L & Marlar R. Severe neonatal protein C deficiency: prevalence and thrombotic risk. Journal of Pediatrics 1991; 119: 793-798.
32. Hagstrom JN, Walter J, Bluebond-Langner R et al. Prevalence of the factor V Leiden mutation in children and neonates with thromboembolic disease. Journal of Pediatrics 1998; 133: 777-781.
33. Heller C, Schobess R, Kurnik K et al. Abdominal venous thrombosis in neonates and infants: role of prothrombotic risk factors-a multicentre case-control study. British Journal of Haematology 2000; 111: 534-539.
34. Nowak-Göttl U, Junker R, Hartmeier M et al. Increased lipoprotein (a) is an important risk factor for venous thrombosis in childhood. Circulation 1999; 100: 743-748.
35. Nowak-Göttl U, Sträter R, Heinecke A et al. Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin and methylenetetrahydrofolate reductase are risk factors of ischaemic stroke in childhood. Blood 1999; 94: 3678-3682.
36. Ehrenforth S, Junker R, Koch HG et al. Multicentre evaluation of combined prothrombotic defects with thrombophilia in childhood. European Journal of Pediatrics 1999; 158: S97-S104.
37. Junker R, Koch HG, Auberger K et al. Prothrombin G20210A gene mutation and further prothrombotic risk factors in childhood thrombophilia. Arteriosclerosis, Thrombosis and Vascular Biology 1999; 19: 2568-2572.
38. Vielhaber H, Ehrenforth S, Koch HG et al. Cerebral venous thrombosis in infancy and childhood: role of genetic and acquired risk factors of thrombophilia. European Journal of Pediatrics 1998; 157: 555-560.
39. Canadian Pediatric ischaemic Stroke Study Group, DeVeber G & Andrew M. Cerebral sinovenous thrombosis in children. New England Journal of Medicine 2001; 345: 417-423.
40. Riikonen RS, Vahtera EM & Kekomäki RM. Physiological anticoagulants and activated protein C resistance in childhood stroke. Acto Paediatrica 1996; 85: 242-244.
41. Zenz W, Bodo Z, Plotho J et al. Factor V Leiden and prothrombin gene G20210A variant in children with stroke. Thrombosis and Haemostasis 1998; 80: 763-766.
42. Kenet G, Sadetzki S, Murad H et al. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischaemic stroke in children. Stroke 2000; 31: 1283-1288.
43. Günther G, Junker R, Sträter R et al. Symptomatic ischaemic stroke in full-term neonates: role of acquired and genetic prothrombotic risk factors. Stroke 2000; 31: 246-251.
44. Laeson SE, Butler D, Enayat MS & Williams MD. Congenital thrombophilia and thrombosis: a study in a single centre. Archives of Disease in Childhood 1999; 81: 176-178.
45. Bonduel M, Hepner M, Sciuccati G et al. Prothrombotic abnormalities in children with venous thromboembolism. Journal of Pediatric Hematology Oncology 2000; 22: 66-72.
46. Mudd SH, Skovby F, Levy HL et al. The natural history of homocystinuria due to cystathionine-β-synthase deficiency. American Journal of Human Genetics 1985; 37: 1-31.
47. Van Beynum IM, Smeitink JA, den Heijer M et al. Hyperhomocysteinemia: a risk for ischaemic stroke in children. Circulation 1999; 99: 2070-2072.
48. Nowak-Göttl U, Junker R, Kreuz W et al. Risk of recurrent thrombosis in children with combined prothrombotic risk factors. Blood 2001; 97: 858-862.
49. Manco-Johnson MJ, Nuss R, Key N et al. Lupus anticoagulant and protein S deficiency in children with postvaricella purpura fulminans or thrombosis. Journal of Pediatrics 1996; 128: 319-323.
50. Andrew M, Paes B & Johnston M. Development of the hemostatic system in the neonate and young infant. Journal of Pediatric Hematology Oncology 1990; 12: 95-104.
51. Manco-Johnson MJ, Grabowski EF, Hellgreen M et al. Laboratory testing for thrombophilia in pediatric patients. On behalf of the Scientific Subcommittee on Perinatal and Pediatric Thrombosis of the Scientific and Standardization Committee of the International Society of thrombosis and Haemostasis. Thrombosis and Haemostasis 2002; 88: 1243-1244.
52. Lane DA, Mannucci PM, Bauer KA et al. Inherited thrombophilia: Part 2. Thrombosis and Haemostasis 1996; 76: 824-834.
53. Häuseler M, Duyue D, Merz U et al. The clinical outcome after inferior vena cava thrombosis in early infancy. Europeon Journal of Pediatrics 1999; 158: 416-420.
54. Mocan H, Beattie TJ & Murphy AV. Renal venous thrombosis in infancy: long-term follow-up. Pediatric Nephrology 1991; 5: 45-49.
55. Bökenkamp A, von Kries R, Nowak-Göttl U et al. Neonatal renal venous thrombosis in Germany between 1992 and 1994: epidemiology, treatment and outcome. European Journal of Pediatrics 2000; 159: 44-48.
56. Monagle P, Adams M, Mahoney M et al. Outcome of pediatric thromboembolic disease: a report from the Canadian childhood thrombophilia registry. Pediatric Research 2000; 47: 763-766.
57. Monagle P, Michelson AD, Bovill E & Andrew M. Antithrombotic therapy in children. Chest 2001; 119: 344S-370S.
58. Massicotte P, Adams M, Marzinotto V et al. Low molecular weight heparin in pediatric patients with thrombotic disease: a dose finding study. Journal of Pediatrics 1996; 128: 313-318.
59. Dix D, Andrew M, Marzinotto V et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. Journal of Pediatrics 2000; 136: 439-445.
60. Manco-Johnson MJ, Grabowski EF, Hellgreen M et al. Recommendations for tPA thrombolysis in children. On behalf of the Scientific Subcommittee on Perinatal and Pediatric Thrombosis of the Scientific and Standardization Committee of the International Society of thrombosis and Haemostasis. Thrombosis and Haemostasis 2002; 88: 1241-1242.
61. Kirk CR & Qureshi SA. Streptokinase in the management of arterial thrombosis in infancy. International Journal of Cardiology 1989; 25: 15-20.
62. Nowak-Göttl U, Schwabe D, Schneider W et al. Thrombolysis with recombinant tissue-type plasminogen activator in renal venous thrombosis in infancy. Lancet 1992; 340: 1005.
63. Wever ML, Liem KD, Geven WB & Tarke RB. Urokinase therapy in neonates with catheter related central venous thrombosis. Thrombosis and Haemostasis 1995; 73: 180-185.
64. Farnoux C, Camard O, Pinquier D et al. Recombinant tissue-type plasminogen activator therapy of thrombosis in 16 neonates. Journal of Pediatrics 1998; 133: 137-140.
65. Weiner GM, Castle VP, DiPietro MA & Faix RG. Successful treatment of neonatal arterial thrombosis with recombinant tissue plasminogen activator. Journal of Pediatrics 1998; 133: 133-136.
66. Nowak-Göttl U, Auberger K, Halimeh S et al. Thrombolysis in newborns and infants. Thrombosis and Haemostasis 1999; 82: S112-S116.
67. Manco-Johnson MJ, Nuss R, Krupski W et al. Combined thrombolytic and anticoagulant therapy for venous thrombosis in children. Journal of Pediatrics 2000; 136: 446-453.
68. Marlar RA, Montgommery R & Broeckmans AW. Diagnosis and treatment of homozygous protein C deficiency. Journal of Pediatrics 1989; 114: 528-534.
69. Dreyfus M, Magny JF, Bridey F et al. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with purified protein C concentrate. New England Journal of Medicine 1991; 32S: 1565-1568.
70. R) in four children with heparin-induced thrombocytopenia type II. Acta Paediatrica 2001; 90: 7657-7677.
71. Streif W, Andrew M, Marzinotto V et al. Analysis of Warfarin therapy in pediatric patients: a prospective cohort study of 319 patients. Blood 1999; 94: 3007-3014.
72. Straeter R, Kurnik K, Heller C et al. Aspirin versus low-dose low-molecular-weight heparin: antithrombotic therapy in paediatric ischaemic stroke patients: a prospective follow-up study. Stroke 2000; 32: 2554-2558.